Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aprepitant for prevention of chemotherapy-induced nausea and vomiting in children with cancer
IRCT20200819048455N1Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of aprepitant in chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by Iran University of Medical Sciences. Primary endpoints: Rate of nausea and vomiting, Number of vomiting episodes and 1 more. Started May 2020; status: completed.
02
Drugs
aprepitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on IRCT20200819048455N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200819048455N1.